Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Albumin for PICD Prevention in Cirrhosis
NCT06892535Phase 4Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Feb 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of albumin (human) in Paracentesis-Induced Circulatory Dysfunction (PICD) (2 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Incidence of Paracentesis Induced Circulatory Dysfunction at 7 days. Started Feb 2024; status: completed.
02
Drugs
albumin (human)
03
Conditions
Paracentesis-Induced Circulatory Dysfunction (PICD)
Beyond the preview
Go deeper on NCT06892535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06892535.